Intellectual Property - February 10, 2015
Novo to Seek IPO for NNIT
Novo Nordisk A/S is seeking an Initial Public Offering (IPO) of NNIT A/S on NASDAQ OMX Copenhagen A/S (Nasdaq Copenhagen). NNIT is a wholly-owned subsidiary of Novo Nordisk A/S and one of Denmark’s leading IT service providers and consultancies. The company has been considering spinning off NNIT since last January, when it named a new […]
Companies - February 9, 2015
Novo Nordisk Files Annual Reports
Novo Nordisk A/S has filed its Annual Report 2014 on Form 20-F for the financial year 2014 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2014. The reports are available at the SEC’s website, www.sec.gov, as well as on novonordisk.com. Shareholders and ADR holders may receive a hard copy of […]
Drug Development Pharma - February 5, 2015
FDA OKs Novo Growth Drug
The U.S. Food and Drug Administration (FDA) has granted approval of Novo Nordisk’s Norditropin® FlexPro® 30 mg/3.0 mL, a prefilled injection pen for patients with growth hormone-related disorders. The FlexPro® 30 mg/3.0 mL device complements the existing FlexPro® products. “Novo Nordisk is committed to advancing growth hormone delivery devices with patients in mind,” said Eddie Williams, […]
Pharma Business - February 2, 2015
Profits for Novo Nordisk in 2014
Novo Nordisk increased operating profit in local currencies by 13 percent and by 10 percent in Danish kroner to DKK 34.5 billion in 2014. Sales growth of 8 percent in local currencies was driven by increased sales of Levemir® and Victoza®. Sales also increased by 6 percent in Danish kroner to 88.8 billion. Gross margin improved […]
New Market - January 27, 2015
Novo to Market Saxenda in U.S.
Novo Nordisk plans to put 500 U.S. sales reps, or about one-sixth of that country’s sales force, to work marketing its newly-approved weight-loss drug Saxenda, a reformulated version of diabetes drug Victoza (liraglutide). In an interview with the Financial Times, Novo Chief Science Officer Mads Krogsgaard Thomsen said his company is looking to generate at […]
Drug Development Pharma - January 23, 2015
Novo’s Saxenda Gets Approval
The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive ruling for the use of Novo Nordisk’s Saxenda® (liraglutide 3 mg) in the treatment of obesity, according to a statement from the company. The CHMP recommends that Saxenda® be prescribed as an adjunct to a reduced-calorie diet and increased […]
